SeNostic Health’s proprietary SeedCycler® technology platform enables a precise and early differential diagnosis of multiple neurodegenerative disorders such Alzheimer’s disease, dementia with Lewy-bodies and Parkinson’s disease.
Seed-biomarkers are fragments of disease-specific protein aggregates present in tissues and body fluids years before the onset of disease. Our platform measures the seeding activity of these biomarkers with high sensitivity and will allow for a mapping to specific disease pathologies.
The unique SeedCycler® technology is appropriate for the detection and differentiation of seeds formed by any type of protein, and can thus differentiate various co-pathologies and strains of disease.
The potential makes our technology uniquely suited for today’s clinical diagnostic needs, for future preclinical diagnostics and for the stratification and follow-up of current pharmaceutical clinical trials.
Our SeedCycler® platform makes use of a proprietary mechanical sample processing technology. This allows us to detect and characterize the pathology-specific seeding activities in different tissues and body fluids.
The same basic technology can be applied to any seed-forming protein. Thus, we can expand our assay portfolio based on our customers’ needs.
Our key advantages:
Chief Scientific Officer
Phone: +49 511 47071181
E-mail: Send message